Disease variants of FGFR3 reveal molecular basis for the recognition and new roles for Cdc37 in Hsp90 chaperone system by Bunney, TD et al.
ArticleDisease Variants of FGFR3 Reveal Molecular Basis
for the Recognition and Additional Roles for Cdc37 in
Hsp90 Chaperone SystemGraphical AbstractHighlightsd Several disease-linked mutations convert FGFR3 to a
stronger client of Hsp90/Cdc37
d Enhanced interaction with Cdc37 is underpinned by a
weakened N-lobe network
d Cdc37 binding to unrelated kinases induces their common,
extensive remodeling
d Kinase remodeling and the kinase/Cdc37 architecture allow
recognition by Hsp90Bunney et al., 2018, Structure 26, 446–458
March 6, 2018 ª 2018 The Author(s). Published by Elsevier Ltd.
https://doi.org/10.1016/j.str.2018.01.016Authors
Tom D. Bunney, Alison J. Inglis,
Domenico Sanfelice, ...,
Roger L.Williams, Alexander L. Breeze,
Matilda Katan
Correspondence
t.bunney@ucl.ac.uk (T.D.B.),
a.l.breeze@leeds.ac.uk (A.L.B.),
m.katan@ucl.ac.uk (M.K.)
In Brief
In their work, Bunney et al. propose a
model in which the cochaperone Cdc37
plays a dual role in binding and
remodeling its kinase clients, thus
allowing recognition by the chaperone,
Hsp90. The overall architecture of a
Cdc37/FGFR3 complex is also presented.
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Receptor tyrosine kinase FGFR3 is involved in many
signaling networks and is frequently mutated in
developmental disorders and cancer. The Hsp90/
Cdc37 chaperone system is essential for function of
normal and neoplastic cells. Here we uncover the
mechanistic inter-relationships between these pro-
teins by combining approaches including NMR,
HDX-MS, and SAXS. We show that several disease-
linked mutations convert FGFR3 to a stronger client,
where the determinant underpinning client strength
involves an allosteric network through the N-lobe
and at the lobe interface. We determine the architec-
ture of the client kinase/Cdc37 complex and demon-
strate, together with site-specific information, that
binding of Cdc37 to unrelated kinases induces a
common, extensive conformational remodeling of
the kinase N-lobe, beyond localized changes and in-
teractions within the binary complex. As further
shown for FGFR3, this processing by Cdc37 deacti-
vates the kinase and presents it, in a specific orienta-
tion established in the complex, for direct recognition
by Hsp90.
INTRODUCTION
Protein folding is a fundamental process guarded by the proteo-
stasis network, including the Hsp90 family of chaperones, which
facilitate the maturation of a wide range of client proteins. The
Hsp90 clients are enriched in signal transduction components,
such as protein kinases, which are crucial in regulating diverse
cellular functions (Karagoz and Rudiger, 2015; Taipale et al.,
2010). Hsp90 interacts with its clients thorough the involvement
of different classes of cochaperones to exert marked effects on
physiological and evolutionary processes as well as disease446 Structure 26, 446–458, March 6, 2018 ª 2018 The Author(s). Pub
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require kinase-specific cochaperone Cdc37 (Jarosz et al.,
2010; Karagoz and Rudiger, 2015; Valastyan and Lindquist,
2014). In cases where proteins acquire pathological functions
through mutation, such mutations often also destabilize protein
structure. Hsp90 can rescue their folding or stability defects,
thus enabling emergence of new or aberrant functions;
among examples are Hsp90-dependent oncogenic variants
with point-mutations, deletions or fusions, including kinases
vSrc, HER2, BCR-ABL, B-Raf, and ELM4-ALK (Valastyan and
Lindquist, 2014).
Among receptor tyrosine kinases, fibroblast growth factors re-
ceptors (FGFRs) have been linked to aberrant signaling in several
developmental syndromes and a broad range of malignancies;
this evidence has been accompanied by rapid progress in tar-
geting FGFRs (Dieci et al., 2013; Katoh, 2016). It has also been
reported that FGFRs, and in particular FGFR3, are clients for
the Cdc37/Hsp90 chaperone machinery in various cellular sys-
tems and that the dependence on the chaperone is further
enhanced for some cancer-associated FGFR gene fusion prod-
ucts (Acquaviva et al., 2014; Jin et al., 2011; Laederich et al.,
2011; Taipale et al., 2012). It is, however, not clear how dis-
ease-linked point mutations in FGFR affect interactions with
Cdc37 and Hsp90. Moreover, as for other client kinases, molec-
ular features underpinning such interactions remain elusive.
Studies of the factors that govern the Cdc37/Hsp90 client sta-
tus of protein kinases have failed to identify involvement of any
common, specific kinase structural motifs. Rather, the key deter-
minant appears to be global thermal stability, presumably related
to the abundance and properties of their meta-stable folds (Boc-
zek et al., 2015; Taipale et al., 2012, 2013). It is well established
that Cdc37 plays an obligate role in recognition and recruitment
of kinases to Hsp90 as substrates (notably, client kinases are not
recognized by Hsp90 in the absence of Cdc37) (Karagoz and Ru-
diger, 2015; Taipale et al., 2012). Structural andmolecular mech-
anistic studies of binary and ternary interactions have mainly
focused on two kinases, Cdk4 and B-Raf (Eckl et al., 2015; Ker-
amisanou et al., 2016; Polier et al., 2013; Vaughan et al., 2006;
Verba et al., 2016). Despite some detailed insights, it remains alished by Elsevier Ltd.
commons.org/licenses/by/4.0/).
challenge to generalize implications of these studies beyond the
specific kinases exemplified. Furthermore, precise molecular
features that determine or tune the level of kinase ‘‘clientness’’
remain undefined. Similarly, structural information for the ki-
nase/Cdc37 complex is lacking, as is an understanding of the
extent, sites, and consequences of conformational changes in
kinases following binding to Cdc37.
Here we focus on FGFRs, a structurally and dynamically well-
defined system, that has not been previously studied as a
Cdc37/Hsp90 client in the mechanistic and structural contexts.
Together with comparative observations for an established
strong client, B-Raf, we address some of the key outstanding
questions about client kinases by applying a range of methods,
including nuclear magnetic resonance (NMR), hydrogen/deute-
rium exchange mass spectrometry (HDX-MS), and small-angle
X-ray scattering (SAXS). After establishing that clinically relevant
FGFR3 variants that become better clients are less-stable pro-
teins, we highlight an allosteric network as a crucial determinant
of kinase stability and consequently of the recognition by Cdc37.
Furthermore, we describe multiple sites of interaction and the
overall architecture of the FGFR3 kinase/Cdc37 complex. Impor-
tantly, we also establish the consequences of Cdc37 binding and
show very extensive remodeling of FGFR3 kinase and similar
changes in B-Raf. We propose that, in the kinase/Cdc37 com-
plex, the remodeled regions of the partially inactivated kinase
are accessible for the recognition by Hsp90, ultimately resulting
in protection and refolding.
RESULTS
Differences between FGFR1-4 and FGFR3 Disease-
Linked Variants in the Ability to Form Complexes with
Cdc37 and Hsp90
To further characterize FGFR/Cdc37/Hsp90 complexes identi-
fied in cellular settings (Laederich et al., 2011; Taipale et al.,
2012), we performed reconstitution from purified components
to first show that ternary and binary complexes with wild-type
(WT) FGFR3 kinase domain (henceforth denoted FGFR3WT)
can be assembled in vitro. The complexes were analyzed by
size-exclusion chromatography (SEC) and pull-down experi-
ments (Figures 1 and S1). We quantified the amount of FGFR3WT
incorporated in the ternary complex under defined condi-
tions (ratio FGFR3WT:pCdc37:Hsp90, 1:1:2) and found that
12%–17% was present in the complex. Under the same condi-
tions, we have not observed any FGFR1, 2, or 4 kinase domain
in ternary complexes. We also compared the unrelated Ser/Thr
B-Raf kinase domain, a well-established ‘‘strong’’ Cdc37 client,
using a variant incorporating the V600E mutation as well as a
number of other changes to ensure solubility (designated as
sB-RafV600E [Tsai et al., 2008]), which, as expected, demon-
strated higher occupancy for both ternary and binary complexes
than FGFR3WT (Figures 1A, 1B, and S1).
We further extended this in vitro analysis to a panel of over 20
cancer mutations in the kinase domain of FGFR3 some of which
overlap with mutations found in developmental disorders.
Recently, our analysis of this panel identified a number of muta-
tions that increase non-stimulated kinase activity (including
N540K and K650E substitutions) among many other (mostly
infrequent) mutations that have no such effect (Patani et al.,2016). Using the same panel, we tested the ability of these vari-
ants of FGFR3 kinase domain (hereafter denoted FGFR3N540K,
FGFR3K650E, etc.) to form binary and ternary complexes, using
SEC and a pull-down assay (Figures 1C, 1D, S1E, and S2A).
We identified three variants, FGFR3E466K, FGFR3I538F, and
FGFR3N540K, which show higher occupancies in complexes
compared with the WT or the K650E hotspot mutation (Figures
1C and 1D). Consistent with this, we measured KD values for
binding of Cdc37 to FGFR3I538F and to FGFR3WT using
isothermal titration calorimetry (ITC), and found that Cdc37
bound tightly to FGFR3I538F with a KD of 1.8 mM, while binding
to the WT variant was too weak to be detectable by ITC, indi-
cating a KD > mM (Figure S1F). Based on the comparative SEC
and pull-down data (Figures 1C, 1D, and S1E) it is expected
that the KD for FGFR3
E466K and FGFR3N540K would be within
the range of 1–2 mM. Although these values are higher than the
previously reported KD for a variant of B-Raf (0.2 mM) (Polier
et al., 2013), for a relative comparison of FGFR3 kinases we refer
to FGFR3WT as a ‘‘weak’’ client, and to FGFR3E466K, FGFR3I538F,
and FGFR3N540K as ‘‘strong’’ clients.
Among the variants that show a marked increase in incor-
poration in both binary and ternary complexes, FGFR3E466K,
FGFR3I538F, and FGFR3N540K (Figures 1C and 1D), only in the
case of FGFR3N540K is kinase activity greatly enhanced
(FGFR3E466K is similar to FGFR3WT and FGFR3I538F has slightly
reduced kinase activity) (Patani et al., 2016). To test a possible
correlationwith protein stability, we further performedan analysis
of kinase domain thermal stability for the panel of cancer muta-
tions, WT FGFR1-4, and sB-RafV600E. As shown in Figure 1E,
FGFR3WT is less stable compared with FGFR1, 2, and 4, while
the stability of FGFR3E466K, FGFR3I538F, and FGFR3N540K is
further compromised to a level comparable with the thermal sta-
bility of the sB-RafV600E variant. In the case of the thermo-labile
FGFR3 variants, recognition by an anti-FGFR3 antibody using
ELISA was also enhanced. The highly active FGFR3K650E had
similar thermal stability andantibody recognition as the FGFR3WT
(Figures 1E and 1F). All other FGFR3 variants had stability and
Cdc37 binding similar to the FGFR3WT (Figure S2). Thus, using
this comprehensive panel, we found that, while the activity
among tested kinases differs considerably irrespective of the
strength of Cdc37 binding, the observed decrease in thermal sta-
bility correlateswell with enhancedclient status. Furthermore,we
also established that binding of FGFR3 inhibitors that reduce for-
mation of binary and ternary complexes, correlates with the in-
crease in thermal stability of the inhibitor-bound kinase (Figures
S3A–S3C). Differences in antibody recognition (Figure 1F)
provide further supporting evidence that distinct molecular prop-
erties, which do not correlate with the kinase activity, are specif-
ically associated with stronger clients.
Using the FGFR3E466K variant, we also obtained some further
information of broader relevance for kinase/Cdc37 interactions.
Consistent with previous observations for other kinases (Polier
et al., 2013; Oberoi et al., 2016), we have found that phosphory-
lation of Cdc37 (on S13 by CK2) has no effect on the binary com-
plex, but enhances formation or stability of the ternary complex
(Figures S4A and S4B). However, in contrast to a previous report
(Liu and Landgraf, 2015), our data suggest that the change in
Cdc37 phosphorylation status is not linked to a conformational
change in this protein (Figure S4C).Structure 26, 446–458, March 6, 2018 447
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Figure 1. Interaction of FGFR Kinase Domains and FGFR3 Variants with Cdc37 and Hsp90
(A) SEC of isolated components Hsp90, Cdc37, and FGFR3WT (top panels) and of their mixture (ratio 2:1:1), showing the ternary complex (fractions T1-T3) and free
FGFR3WT (fractions F1-F3) (bottom panel). The graphs (below) showquantitation of the incorporation of kinases in the ternary complex for FGFR1, 2, 3, and 4 (left),
and for sB-RafV600E (right). The error bars represent the SD (n = 3).
(B) Comparison of FGFR3WTwith sB-RafV600E using a pull-down binding assay using immobilized Cdc37. A quantification of the amount of kinase bound is shown
in the lower panel.
(C) SEC of FGFR3E466K (top panel). SEC of a 1:1 mixture with Cdc37 shows the binary complex (fraction B1-B3) and free kinase (fractions F1-F3) (middle panel)
and of a mixture with both Hsp90 and Cdc37 (ratio 2:1:1) showing the ternary complex (fraction T1-T3), a small amount of the binary complex (fractions B1-B3)
and free kinase (fractions F1-F3) (bottom panel). The graph (below) shows quantification of FGFR3 in the ternary complex for the FGFR3WT, FGFR3E466K,
FGFR3I538F, FGFR3N540K, and FGFR3K650E. The error bars represent the SD (n = 3).
(D) Binding of FGFR3E466K to immobilized Cdc37 (left) and comparison of binding of FGFR3WT with FGFR3E466K, FGFR3I538F, FGFR3N540K, and FGFR3K650E in this
pull-down assay (right). The error bars represent the SD (n = 3).
(E) Comparison of melting temperatures of kinase domains of FGFR1-4, sB-RafV600E, and FGFR3E466K, FGFR3I538F, FGFR3N540K, and FGFR3K650E. The error bars
represent the SD (n = 4).
(F) Recognition of FGFR3WT, FGFR3E466K, FGFR3I538F, FGFR3N540K, and FGFR3K650E by a polyclonal antibody prepared against a peptide corresponding to
FGFR3 amino acid residues 467–495 (LS-C214248, Lifespan BioSciences). See also Figures S1–S4.Characterization of Weak versus Strong Client Kinases
Destabilizing mutations in FGFR3 kinase domain are located
within the N-terminal part of the N-lobe (E466K) and within fea-448 Structure 26, 446–458, March 6, 2018tures described as the ‘‘DFG latch’’ (I538F) and ‘‘molecular brake’’
(N540K), previously linked toN-lobe rotation and activationmech-
anisms (Chen et al., 2017). Based on our further analysis of the
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Figure 2. Comparison of Overall Structural Differences between
Client Kinase Domains
(A) The FGFR allosteric network running through the N-lobe and linking to the
activation loop and the lobe interface. Cartoon representation of an FGFR3WT
model, with amino acid residues corresponding to sites of disease-linked
mutations found to destabilize the kinase domain colored blue and all other
residues within the network shown as pink.
(B) Normalized thermal-shift curves for the indicated kinase domain variants.
(C) A global deuteration profile of FGFR3 proteins. A linear plot of deuteration
levels across FGFR3WT (blue) and two variants FGFR3E466K (red) and
FGFR3I538F (green). The percentage of deuteration at the 0.3 s time point for
each peptide is plotted against the peptide mid-point (i); secondary structure
and key features of the kinase domain region are also shown and mutations
indicated by dotted lines (bottom). The data plotted aremeans ±SD (n = 3). The
error bars smaller than the icon are omitted.
(D) A global deuteration profile for the kinase domain of sB-RafV600E; the plot
(top) and secondary structure (bottom) are represented as in (C).available data (including over 30 crystal structures of FGFRkinase
domains), all three mutated residues are likely to be connected
within a larger allosteric network (Figure 2A). In addition to local
changes, perturbations in this network are expected to have, at
least to some degree, an effect on the overall structural integrity
of the N-lobe and the lobe interface. To test this possibility, our
further experiments aimed toprovidedirect structural information.
Detailed comparison of FGFR3E466K, FGFR3I538F, and
FGFR3N540K reveals some differences in thermal-shift curves be-
tween these less stable variants; curves for FGFR3E466K and
FGFR3N540K exhibit greater basal fluorescence (suggesting
greater hydrophobic exposure) even at lower temperatures
(20C) (Figure 2B). Also, expression of FGFR3E466K and
FGFR3N540K appears to be more impaired (expression levels
WT > I538F >> E466K > N540K), and amounts of FGFR3N540K
are insufficient for more extensive characterization. Therefore,
to further assess the impact of mutations on the structure, we
performed HDX-MS using only FGFR3WT, FGFR3I538F, and
FGFR3E466K and NMR spectroscopy using the two most highly
expressed proteins, FGFR3WT and FGFR3I538F.
For HDX-MS, we compared the extent of deuteration in
FGFR3WT, FGFR3I538F, and FGFR3E466K with that in sB-RafV600E
(Figures 2C and 2D). For all proteins, there are some common
features that are characterized by very low (aC and aE helices)
or very high (N and C termini, A loop, and regions of b strands)
rates of solvent exchange. Interestingly, among FGFR3 kinase
domains, the less stable FGFR3E466K has a higher percentage
of deuteration in peptides derived from across the entire
N-lobe (Figure 2C). This is consistent with the key position of
E466 residue within the N-lobe allosteric network encompassing
the N terminus (including L459), b4-b5 linker (T546 and L551),
and aC helix (L519, V523 and M526), which is further connected
to other elements of the network (Figure 2A). In contrast, HDX
changes in I538F are less significant and similar to the WT, sug-
gesting a subtler effect that is undetectable by HDX-MS, but
nevertheless sufficient to considerably enhance binding to
Cdc37, as corroborated by our ITC data (Figure S1F).
To gain more detailed insights into differences between the
FGFR3WT and FGFR3I538F that represent weak and strong cli-
ents, respectively, we compared them using NMR spectros-
copy. We have previously applied NMR to analyze FGFR3WT
(Bunney et al., 2015; Patani et al., 2016), aided by our full NMR
assignment of FGFR1 (Klein et al., 2015; Vajpai et al., 2014).Structure 26, 446–458, March 6, 2018 449
A C
B
Figure 3. Comparison of FGFR3 Variants by NMR
(A) Superimposed 2D amide TROSY-HSQC experiments for FGFR3WT (blue) and FGFR3I538F mutant (green). Comparison was performed at 283K. Highlighted in
four boxes (1–4) are the most prominent differences; new sharp peaks in box 1 are indicated by (*).
(B) NMR changes were quantified by CSP analysis. The histogram shows in green the successfully assigned residues transferred from WT at 298K.
(C) FGFR3 residues (shown as side chains and labeled) involved in the allosteric network encompassing the N-lobe and the N-lobe/C-lobe interface are high-
lighted in a cartoon and surface representation of the kinase. The enlarged N-lobe/C-lobe interface is shown in the inset below with F638 (from the DFG motif),
I538 (part of the ‘‘DFG latch’’), and N540 (from the ‘‘molecular brake’’) highlighted. Underlined residues (E466 within the N-terminal part of the N-lobe and I538 and
N540 at the interface), corresponding to mutations that destabilize FGFR3 kinase domain, are shown as a part of an extensive, interconnected allosteric network
highlighted by NMR changes. See also Figure S5.Here, using a combination of selective labeling and 3D experi-
ments, we were able to achieve a backbone assignment for
FGFR3WT of 75%. A direct comparison of the 2D 1H-15N
TROSY-HSQC spectra of FGFR3WT and the less stable
FGFR3I538F variant was possible by reducing the temperature
to 283K (in these conditions FGFR3I538F samples were stable
long enough to acquire 2D spectra) (Figure S5). Overall, spectra
of FGFR3WT and FGFR3I538F are similar (Figure 3A), confirming
that the global structure of the two variants is conserved. As ex-
pected the aromatic ring current arising from the I538F mutation
has a strong local effect on the chemical shifts of the neighboring
amino acid residues K536 and N537 (Figure 3A, inserts 2 and 3).
There are also further effects on the ‘‘DFG latch,’’ including
disappearance of F636 and D635 and major shifts of G637 and
A639 in the A-loop region (Figure 3A, inserts 1 and 4). We noted
significant chemical shift perturbations (CSPs) for several amino
acid residues within the allosteric network (E556, K536, I532,
M529, and E525) (Figures 3B and 2A), which might result in
reduced overall stability of the N-lobe and its interface with the
C-lobe. Strikingly, in the spectrum of FGFR3I538F we observed
the appearance of new, sharp peaks in the random-coil chemical
shift region that are not present in FGFR3WT (Figure 3A, insert 1).450 Structure 26, 446–458, March 6, 2018We interpret these peaks as signaling localized unfolding that
arises from perturbation of the extended allosteric network due
to the I538F substitution, and that likely contributes to the
reduced thermal stability of this variant. As summarized in Fig-
ure 3C, NMR data highlight changes consistent with the pro-
posed allosteric connectivity, where the I538F mutation results
not only in changes in neighboring residues, but also in de-
creases in overall stability and at the interface between the lobes.
We have also noted that the binding of an FGFR inhibitor,
PD173074, which increases kinase domain thermal stability
was accompanied by prominent CSPs in the N-lobe allosteric
network of FGFR3WT (Figures S3D and S3E). With respect to
localized unfolding, the random-coil peaks, already present in
free FGFR3I538F (but absent from FGFR3WT) (Figure 3A, insert 1)
correlate remarkably to those observed to intensify upon Cdc37
complex formation (see next section and Figure 5).
Molecular Changes in Kinases Following Cdc37 Binding
To identify changes in the kinase architecture that result from the
binding of Cdc37, FGFR3WT, FGFR3I538F, and FGFR3E466K were
analyzed by HDX-MS following the addition of a stoichiometric
excess of Cdc37 (Figures 4 and S6; Table S1). For comparison
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Figure 4. Global Changes in Kinase Domains Following
Interaction with Cdc37
(A) The difference in HDX for FGFR3 variants in their free form and
when in complex with Cdc37. Percent deuteration change was
calculated by subtracting the deuteration of each peptide of FGFR3
complexed with Cdc37 from the same peptide of free FGFR3 at the
0.3 s time point. The data plotted are means ± SD (n = 3).
(B) The same depiction as in (A) for sB-RafV600E.
(C) Ribbon representations of FGFR3 and sB-RafV600E kinase do-
mains with HDX differences mapped onto them. Peptides with sig-
nificant changes (<5%) upon addition of excess Cdc37 have been
colored according to the key. For each peptide, the time point with the
largest difference between the free and bound states was used in this
analysis. See also Figure S6 and Table S1.
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Figure 5. Changes in FGFR3 Following the Interaction with Cdc37
Assessed by NMR
(A) Selected region of 1H-15N TROSY-HSQC spectra of FGFR3I538F in the
absence and presence of 0.5 equivalents of Cdc37, acquired at 283K (top
subpanel); for comparison, spectra of FGFR3WT (navy) and FGFR3I538F (lime),
both in the presence of 0.7 equivalents of Cdc37 and acquired at 288K are also
shown (bottom subpanel). Coloring of the top subpanel is as in panel (A) The
location of sharp peaks (1–12, numbered according to relative intensity) is
indicated in both panels and red crosses show approximate locations.
(B) Selected spectral regions of FGFR3I538F in the absence (top subpanel) and
presence (bottom subpanel) of 0.5 equivalents of Cdc37, illustrating the
presence of sharp peaks 1, 2, and 7 in the free state and their increased in-
tensity in the complex.
(C) Peak heights of sharp peaks 1–12 in FGFR3I538F in the absence (green) and
presence of 0.25 (maroon) and 0.5 (yellow) equivalents of Cdc37. Assignments
of these peaks are given below their respective peak number.with an established strong client, we again included sB-RafV600E
in the analysis. Using this method, the consequences of the
weak binding to FGFR3WT were barely detectable. However,
binding of Cdc37 to all other kinase variants had a pronounced
effect that, in each case, showed remarkable similarities. Impor-
tantly, a significant portion of the N-lobe shows an increase in
solvent exchange rate while several regions of the C-lobe were452 Structure 26, 446–458, March 6, 2018observed to decrease their exchange rate upon binding (Figures
4A and 4B). Mapping of the peptides which showed differences
in solvent exchange rates on to kinase structures highlighted aC
and the majority of the N-lobe b strands as regions that had dra-
matic increases of their solvent exchange rates upon the addi-
tion of Cdc37 in all kinases (Figure 4C). The regions that show
a reduction in their solvent exchange rates in the C-lobe are
most extensive for the most labile FGFR3E466K variant, and over-
lap with those of FGFR3I538F and sB-RafV600E. These regions
include FGFR3 amino acid residues 592–602, 611–628, 670–
684, and 732–752; in sB-RafV600E the corresponding protected
residues are 568–581, 619–627, and 659–707.
HDX-MS does not afford a direct map of protein-protein inter-
action sites. Nevertheless, regions that experience a decrease in
exchange with solvent upon addition of a binding partner have a
high probability of involvement in protein-protein interfaces (Ko-
nermann et al., 2011). HDX-MS supports very substantial confor-
mational changes in client kinases upon Cdc37 binding that, in
addition to direct interactions, result in a less-structured N-lobe.
To complement the insights from HDX-MS, we again em-
ployed 2D HSQC NMR and performed titration experiments in
which unlabeled Cdc37 (at molar ratios of 0.25 and 0.5) was
added to 15N-labeled samples of FGFR3I538F (Figure 4). Because
of the low-mM KD and 1:1 stoichiometry for binding of Cdc37, as
determined by ITC (Figure S1F), we anticipated that resonances
of the unbound kinase should still be present in these spectra
at 75% and 50%, respectively, of their intensity in the
absence of Cdc37, and that any new resonances arising from
the bound conformation(s) of FGFR3I538F should be significantly
broadened as a result of the large size (82 kDa) of the complex.
Surprisingly, we found that in the presence of Cdc37, FGFR3I538F
resonances were much more extensively reduced in intensity
than suggested by the stoichiometric ratios employed; this im-
plies that exchange between free and Cdc37-bound conforma-
tion(s) of the kinase occurs on an intermediate (microsecond to
millisecond) timescale in the complex, even for this relatively
high affinity interaction. Another striking observation (in the
context of the overall resonance broadening) was the presence
of a number of intense, sharp peaks in the random-coil region
of the spectrum (Figures 5A and 5B). Using a combination of
3D experiments and selective labeling, we were able to assign
these amide resonances to the N-terminal region of the FGFR3
N-lobe (Figure 5C). Although some of the sharp peaks were
already present in the free state and observed as a distinct
feature of FGFR3I538F (as highlighted in Figure 3A), they intensify
notably upon addition of Cdc37, implying that this region be-
comes less folded and more mobile in the complex with the co-
chaperone. Interestingly, titration of FGFR3WT (which binds only
weakly to Cdc37, as determined by ITC [Figure S1F]) with higher
concentrations of the cochaperone also resulted in appearance
of these sharp peaks at identical chemical shifts, despite their
complete absence, as noted above, from the spectrum of free
FGFR3WT (Figure 5A). Our NMR results are thus consistent
with our observations from HDX-MS that Cdc37 causes more
extensive remodeling of the kinase N-lobe (Figure 4); however,
further interpretation of global changes to the kinase by NMR
are currently elusive because of the extent of conformational ex-
change broadening in the large complex. Further analysis using
circular dichroism (CD) to compare FGFR3I538F alone and in
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Figure 6. Changes in Cdc37 Following FGFR3 Kinase Binding and a Structural Model for the Cdc37/FGFR3 Kinase Domain Binary Complex
(A) The difference in HDX for Cdc37 in its free form and when in complex with FGFR3E466K. For the regions covered (residues 29–119 are lacking in the analysis),
percent deuteration change was calculated by subtracting the deuteration of each peptide of Cdc37 complexedwith FGFR3 from the same peptide of free Cdc37
at the 0.3 s time point (left panel). Data plotted are the means ± SD (n = 3). Ribbon representations of a Cdc37 model (based on structures and SAXS data-
SASDBP9) with HDX differences mapped onto them. Peptides with significant changes (<5%) upon addition of excess FGFR3 have been colored according to
the key. For each peptide, the time point with the largest difference between the free and bound states was used in this analysis (right panels). Region of Cdc37
outlined with a dotted line did not yield any data from the HDX-MS analysis.
(B) Surface representations of Cdc37 and FGFR3 kinase domain (depicted at the same scale) with HDX differences between the free and complex formsmapped
and colored according to the key in (A).complex with Cdc37 have shown that global secondary struc-
ture composition is largely preserved (<15% change). Taken
together, our data from HDX-MS, NMR, and CD analyses
support a substantial remodeling of the kinase N-lobe tertiary
structure with transient, localized unfolding, but without large
perturbations within the secondary structure elements.
Molecular Changes in Cdc37 Following Kinase Binding
and Insights into a Kinase/Cdc37 Complex
To analyze molecular changes in Cdc37 resulting from kinase
binding, we used HDX-MS and focused on the FGFR3E466K
variant. As shown in Figure 6A, this analysis did not cover the
entire Cdc37 sequence due to incomplete proteolysis in parts
of the N-terminal sequence. Nevertheless, we identified two re-
gions of Cdc37 that experience decreased HDX: the extreme
N terminus (residues 5–28), and the C-terminal a helices (resi-
dues 302–341). Interestingly, the same regions have recently
been identified in NMR experiments in which Cdc37 was titrated
with sB-RafV600E (Keramisanou et al., 2016). Furthermore, most
of the region of Cdc37 that was not covered by HDX-MS in our
study, appears not to be involved in kinase interaction based
on NMR (residues 40–105) (Keramisanou et al., 2016). In addition
to changes in the N- and C-terminal regions, some smaller
changes in HDX rate were observed by HDX-MS (middle region,residues 219–251 and 270–293; Figures 6A and 6B). Interest-
ingly, changes in this middle region of Cdc37 were previously
observed by NMR and attributed to conformational changes
on complex formation, rather than direct involvement in a binding
interface (Keramisanou et al., 2016).
In contrast to client kinases, which undergo very substantial
changes in solvent exchange rate across the entire structure
(Figure 4), changes in Cdc37 appear to be more localized and
are mainly reflected in decreased solvent exchange rates (Fig-
ure 6). The insights from our HDX-MS analysis (different kinases
show similar changes [Figure 4]; Cdc37 complexed to the
FGFR3E466K variant [Figure 6] shows HDX decreases in the re-
gions previously identified by NMR in sB-RafV600E complexes
[Keramisanou et al., 2016]) suggest sites that could be common
across different kinase-Cdc37 interactions. However, this
knowledge is not sufficient to define the spatial arrangement of
Cdc37 and kinase within a binary complex. A complex of
Cdc37 and FGFR3I538F was therefore further analyzed by syn-
chrotron SAXS (Svergun et al., 2013) to obtain low-resolution in-
sights into the overall architecture of the complex (Figures 7
and S7; Table S2). Scattering curves were recorded for the single
components and for the complex, and all three SAXS curves
analyzed together to provide consistent models (Figure S7).
The parameters of the analysis and the calculated models forStructure 26, 446–458, March 6, 2018 453
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Figure 7. A Structural Model for the Cdc37/FGFR3 Kinase Domain Binary Complex
SAXS envelope for the Cdc37/FGFR3 complex, with Cdc37 in dark and FGFR3 in light gray (top). The best fit for the complex is shown below as cartoon and
surface representations of the kinase domain (green) and Cdc37 (purple). Notable features are labeled and regions identified as protected by HDX-MS shaded in
corresponding colors. See also Figure S7 and Table S2.both the individual components and the complex are summa-
rized in Table S2. Although showing variations at higher resolu-
tion, the models derived from SAXS using both ab initio and
hybrid rigid body approaches converge and predict highly asym-
metric structures with distinct features. Notably, one lobe of the
models is consistently occupied by the paired helices from
Cdc37 (residues 29–119), while FGFR3I538F can be fitted to a
second lobe of the envelope, facing the terminal regions of
Cdc37. Themodel in Figure 7 shows the best fit that is consistent
with themeasured scattering curves. An arrangement for the two
components reveals that N- and C-terminal regions of Cdc37
interact mostly with the C-lobe of the kinase, with the N terminus
extending further toward the N-lobe. As discussed further
(see Discussion) this model, suggesting a multi-site nature of
Cdc37 binding to client kinases, is also consistent with previous
biochemical studies (Eckl et al., 2015; Keramisanou et al., 2016).
We also obtained a model for uncomplexed Cdc37 using SAXS
that suggests that the C- and N-terminal parts are in close prox-
imity (Figures 7 and S7); this model assembles previously deter-
mined structures for the protein lacking the N-terminal region
(127–378) (Roe et al., 2004) and a structure of the isolated N ter-
minus (1–126) (Keramisanou et al., 2016).
The key insights from our structural studies imply that differ-
ences betweenweak and strong client kinases are relatively sub-
tle, but that the interaction with Cdc37 results in substantial
changes, most strikingly an increase in disorder of the N-lobe.
To further substantiate these findings, we performed additional
experiments to monitor how the interaction with Cdc37 affects
kinase activity and how exposure of kinases to different temper-454 Structure 26, 446–458, March 6, 2018atures affects protein-protein interactions (Figure 8). The interac-
tion with Cdc37 results in an inhibition of kinase activity, with the
FGFR3 variants with stronger binding to Ccd37 showing a
more pronounced inhibition of auto-phosphorylation (Figures
8A and 8D). In particular, the inhibition of FGFR3E466K by an equi-
molar concentration of Cdc37 is equivalent to exposure to 0.4 M
urea (Figures 8B and 8D). However, unlike Cdc37, the effects
of urea on all FGFR3 variants is similar (irrespective of their ther-
mal stability differences), highlighting the specificity of Cdc37-
induced unfolding compared with that of urea. The reduction
of kinase activity by Cdc37 is even more marked when Hsp90
is included in the experiment (Figures 8C and 8D).
It has been documented that Hsp90 cannot recognize kinases
in the absence of Cdc37 (Taipale et al., 2012). To test this in our
system, different FGFR3 variants were incubated at increasing
temperatures before being subjected to a pull-down on either
immobilized Cdc37 or Hsp90 (Figure 8E). Although increasing
temperature presumably induced structural instability, we noted
reduced binding to Cdc37. However, at the highest temperature
tested (40C), direct binding of the kinase to Hsp90 was
observed. This is consistent with the notion that recognition of
clients by Cdc37 requires a high degree of structural preserva-
tion of the kinase fold, whereas recognition by Hsp90 relies on
partially folded (or unfolded) structures.
DISCUSSION
We have focused on FGFR kinases, and here describe mo-
lecular determinants that influence recognition by Cdc37, the
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Figure 8. Functional Consequences of
Cdc37 Binding to FGFR3 Kinases
(A) Western blot utilizing antibodies that recognize
phosphorylated tyrosine residues on FGFR3.
Increasing ratios of Cdc37 to kinase are monitored
for the effect on FGFR3WT, FGFR3E466K, and
FGFR3I538F auto-phosphorylation.
(B) As (A) but the effect of increasing urea con-
centration is monitored for its effect on auto-
phosphorylation of FGFR3 variants.
(C) As (A) but the effect of increasing Hsp90/Cdc37
to kinase ratio is monitored for its effect on auto-
phosphorylation of FGFR3 variants.
(D) Decrease in normalized kinase auto-phos-
phorylation (pY654), following addition of Cdc37
(top), urea (middle), or Cdc37 together with Hsp90
(bottom). Data plotted are the means ± SD (n = 3).
(E) Temperature dependence of client kinase
binding to Cdc37 and Hsp90. Immobilized Cdc37
or Hsp90 are utilized to pull down FGFR3 variants
at various temperatures (4C, 15C, 25C, and
40C). Bound protein is visualized using western
blotting with a FGFR3 antibody.architecture of the kinase/Cdc37 complex, the extensive remod-
eling of kinase structure, and its mechanistic and functional
consequences beyond binary complex formation, common to
different client kinases.
FGFR kinases, and in particular FGFR3, have been recognized
as clients of the Cdc37/Hsp90 system in cells (Laederich et al.,
2011; Taipale et al., 2012), and here we demonstrate reconstitu-
tion of FGFR3 complexes in vitro for further mechanistic andstructural studies. We also provide very
comprehensive evidence (Figures 1 and
S1–S4) that supports previously sug-
gested correlation between thermal sta-
bility and the strength of client kinase
recognition by Cdc37 (Taipale et al.,
2012). Furthermore, we highlight the sta-
bility of an allosteric network within the
N-lobe and the lobe interface as the
main determinant of overall stability and
consequently Cdc37 recognition (Figures
2, 3, and S3). We have shown that differ-
ences between weak and strong client ki-
nases can be relatively subtle and involve
the lobe interface as well as some less
well-folded regions within the N-lobe
(Figures 2 and 3). Nevertheless, a high
degree of correct folding into a kinase
structure appears to be essential for
Cdc37 recognition (Figures 2 and 8).
We also show that recognition by
Cdc37 is independent of the activation
status, with one of the two highly onco-
genic variants (N540K) being a very
strong client, while the other (K650E)
binds weakly with an affinity similar to
the WT (Figure 1). This difference likely
reflects distinct activation mechanisms:N540K substitution in the molecular brake (a feature that under-
pins intramolecular inhibitory constraints in the FGFR family
within the N-lobe/lobe interface allosteric network) destabilizes
an inactive conformation, thus facilitating activation, while the
K650E variant introduces a substitution in the A-loop that stabi-
lizes an active conformation by forming additional interactions
(Chen et al., 2017; Huang et al., 2013). These findings also sug-
gest that cancers driven by FGFR3 overexpression (as FGFR3Structure 26, 446–458, March 6, 2018 455
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Figure 9. Insights into Formation, Architecture, and Functional Con-
sequences of the Kinase/Cdc37 Complex
Molecular determinants for differences between strong and weak clients arise
from the degree of connectivity within the N-lobe allosteric network (top left).
Interaction sites, identified on strong client kinases and Cdc37, mediate for-
mation of stable binary complexes with defined structural organization.
Interaction surfaces involve two areas, one formed by interaction between the
C-terminal part of Cdc37 and the kinase C-lobe, and another between the N
terminus of Cdc37 and a lobe interface/N-lobe of a kinase (center, top).
Importantly, Cdc37 binding, via allostery, causes extensive remodeling
affecting the entire N-lobe and results in kinase inactivation (center, bottom).
Because the overall changes are substantial and the less compact, remodeled
regions of the kinase left exposed in the binary complex, the main conse-
quence of this re-modelling is to contribute to direct recognition by Hsp90
(bottom left). Within the ternary complex the kinase becomes further unfolded
and interactions with, and relative orientation to, Cdc37 differ. Ultimately, the
kinase is protected and refolded.appears to be a better client compared with other FGFRs), or by
FGFR3 mutations that further destabilize kinase structure, might
be particularly worthwhile targets for exploration of Hsp90 and
FGFR kinase inhibitor combinations as potential synergistic mo-
lecular therapies aimed at overcoming clinical drug resistance to
kinase inhibitors as single agents.
The architecture of the kinase-cochaperone complex has not
been defined for any of the client kinases, at any resolution.
Based on HDX-MS applied to Cdc37, FGFR3 variants, and an
unrelated sB-RafV600E kinase (Figures 4 and 6) in combination
with the SAXS data for a FGFR3/Cdc37 complex (Figure 7),
we show a relative orientation that could be adopted by various
kinases in a binary complex. Interaction surfaces involve two
areas, one formed by interaction between the C-terminal part
of Cdc37 and the kinase C-lobe, and another between the
N terminus of Cdc37 and a lobe interface/N-lobe of a kinase.
This is consistent with previous studies suggesting a bipartite
nature of Cdc37 binding to client kinases (Eckl et al., 2015; Ker-
amisanou et al., 2016). Although sites of interactions on the
kinase have not been directly analyzed in these studies, an
assumption was made that the indispensable N terminus of
Cdc37 interacts with the ATP-binding pocket at the lobe456 Structure 26, 446–458, March 6, 2018interface based on the Cdc37/kinase inhibitor or Cdc37/ATP
competition (Eckl et al., 2015; Polier et al., 2013). Consistent
with findings by Keramisanou et al. (2016), and a model for a
two-step recognition, it is also possible that following initial in-
teractions that involve the N terminus of Cdc37, features either
pre-existing in strong clients or enhanced by Cdc37 in weaker
clients could stabilize this area of interactions and allow for
cooperative binding that involves distinct sites on Cdc37 (C ter-
minus) and on the kinase (C-lobe).
Our data also suggest differences between Cdc37/kinase
interactions in binary and ternary complexes. A recent cryoelec-
tron microscopy structure of a Cdk4/Cdc37/Hsp90 ternary com-
plex is consistent with multiple binding sites between the kinase
and Cdc37, but does not include extensive involvement of the
kinase C-lobe in these interactions; instead, a very localized
interaction covering a short segment of the C-lobe at the lobe
interface has been implicated (Verba et al., 2016). Because the
surface area of Cdc37 that becomes protected in binary com-
plexes is larger than if restricted to only kinase N-lobe and the
lobe interface (Figures 6 and 7), it is conceivable that further re-
arrangements could be taking place in the ternary complex that
also contains Hsp90. Furthermore, the separation of the N- and
C-lobes of Cdk4 observed in the ternary complex, which involves
formation of a linker consisting of unstructured b4 and b5
strands, is not supported by the analysis of the FGFR3/Cdc37
binary complex (either by HDX-MS, NMR, or CD), while our
observation of more stringent kinase inhibition within the ternary
complex suggests further changes caused by the chaperone
(Figures 4, 5, and 8). In addition, the Cdk4/Cdc37 architecture
seen within the ternary complex (Verba et al., 2016) would be
energetically unfavorable without further stabilizing interactions
of both proteins with Hsp90.
The mechanistic model proposed here (Figure 9) emphasizes
extensive kinase structural and functional consequences of
Cdc37 binding. These go beyond limited, localized changes
that enhance the strength of binary client-cochaperone com-
plexes, as proposed previously (Keramisanou et al., 2016). Un-
expectedly, our data show that, in unrelated clients (FGFR3
variants and sB-RafV600E), there is a similar, large conforma-
tional change upon Cdc37 binding, whereby the C-lobe shows
a decrease in solvent exchange rate, indicating that it repre-
sents the direct binding site for Cdc37, while the N-lobe shows
significantly increased solvent exchange rates (Figure 4). We
argue that these increased rates of deuteration suggest remod-
eling with a degree of destabilization of the N-lobe and the
impact of this effect is reflected in Cdc37’s ability to inhibit ki-
nase auto-phosphorylation (Figure 8). The phenomenon of
N-lobe remodeling is further supported by our NMR data that
show the Cdc37-induced emergence of a more flexible, tran-
siently unfolded, N terminus (Figure 5). In our SAXS model,
the kinase N-lobe is positioned to protrude (rather than be
embedded) in the binary complex (Figure 7). Based on previous
findings showing that Hsp90 interacts with the unfolded regions
in its clients (Karagoz and Rudiger, 2015; Rohl et al., 2013), also
supported here for FGFR3 (Figure 8), a likely implication is
that the destabilized N-lobe provides a recognition site for the
recruitment of and/or additional interactions with Hsp90 within
a ternary complex. Moreover, this model of client destabiliza-
tion to facilitate transfer to Hsp90 is also consistent with a
well-supported model proposed for the glucocorticoid receptor
(GR). Hsp70, which in this case facilitates client delivery to
Hsp90, inactivates GR through partial unfolding (Kirschke
et al., 2014). Cdc37 could have an analogous role for kinases
to that of Hsp70 in the GR/Hsp70/Hsp90 system. Our mecha-
nistic model (Figure 9) therefore provides a link between previ-
ous insights into structural domains of Cdc37 involved in entry
of a client kinase into its chaperone cycle (Keramisanou et al.,
2016) and the recent insight into the structural endpoint,
namely a radically unfolded kinase within the ternary complex
(Verba et al., 2016).STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-FGFR3 Abcam Cat# ab204953
HRP-conjugated rabbit polyclonal anti FGFR3 LifeSpan Bioscience Cat# LS-C214248
Rabbit polyclonal anti-FGFR1 phospho-Tyrosine 654 AbCam Cat# ab70959; RRID:AB_1268885
Rabbit ployclonal anti-FGFR1 phospho-Tyrosine 766 AbCam Cat# ab59180; RRID:AB_2293927
Goat anti-rabbit HRP-conjugate GE Healthcare Cat# NA934V
Bacterial and Virus Strains
C41 (DE3) Lucigen Cat# 60442-1
XL-10 Gold Stratagene Cat# 200314
Chemicals, Peptides, and Recombinant Proteins
Dovitinib Stratech Scientific Ltd. Cat# S1018-SEL
AZD4547 Stratech Scientific Ltd. Cat# S2801-SEL
PD173074 Stratech Scientific Ltd. Cat# 366905-USB
Rhamnose Alfa Aesar Cat# A16166
Spectinomycin Apollo Scientific Ltd. Cat# BIS0147
DNAse I Sigma Cat# D5025
Ulp1 protease Expressed in-house N/A
DMSO Sigma Cat# D2650
ATP Thermo Fisher Scientific Cat# R0441
SYPRO Orange Dye Thermo Fisher Scientific Cat# S6650
Pfu Ultra II Agilent Cat# 600670
Deposited Data
FGFR3 backbone NMR assignment apo BMRB 27082
FGFR3 backbone NMR assignment PD complex BMRB 27083
SAXS Cdc37 model https://www.sasbdb.org/ SASDBP9
SAXS Cdc37-FGFR3 I538F complex https://www.sasbdb.org/ SASDBQ9
SAXS FGFR3 I538F https://www.sasbdb.org/ SASDBR9
Oligonucleotides
FGFR3E466K mutagenesis fw
GACCCCAAATGGAAGCTGTCTCGGGCC
This paper N/A
FGFR3E466K mutagenesis rv
GGCCCGAGACAGCTTCCATTTGGGGTC
This paper N/A
FGFR3I538F mutagenesis fw
GAAACACAAAAACTTCATCAACCTGCTG
This paper N/A
FGFR3I538F mutagenesis rv
CAGCAGGTTGATGAAGTTTTTGTGTTTC
This paper N/A
FGFR3N540K mutagenesis fw
CAAAAACATCATCAAACTGCTGGGCGCC
This paper N/A
FGFR3N540K mutagenesis rv
GGCGCCCAGCAGTTTGATGATGTTTTTG
This paper N/A
FGFR3K650E mutagenesis fw
CGACTACTACAAGGAGACAACCAACGGCC
This paper N/A
FGFR3K650E mutagenesis rv
GGCCGTTGGTTGTCTCCTTGTAGTAGTCG
This paper N/A
(Continued on next page)
Structure 26, 446–458.e1–e8, March 6, 2018 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
pOPINS FGFR3WT Kinase Domain (Bunney et al., 2015) N/A
pOPINS FGFR3E466KKinase Domain This work N/A
pJ821 FGFR3I538F Kinase Domain This work N/A
pJ821 FGFR3N540K Kinase Domain This work N/A
pJ821 FGFR3K650E Kinase Domain (Patani et al., 2016) N/A
pJ821 sB-RafV600E Kinase Domain This work N/A
pET28 Cdc37 Gift from Cara Vaughan N/A
pRSET Hsp90 Gift from Cara Vaughan N/A
pTWO Casein Kinase II Gift from Cara Vaughan N/A
Software and Algorithms
CCPNMR Analysis (Vranken et al., 2005) http://www.ccpn.ac.uk/v2-software/
software/analysis
NMRPipe and NMRDraw (Delaglio et al., 1995) https://www.ibbr.umd.edu/nmrpipe/
ATSAS 2.8 (Franke et al., 2017) https://www.embl-hamburg.de/biosaxs/
software.html
Image Studio Lite LiCor https://www.licor.com/bio/products/software/
image_studio_lite/
Mascot distiller Matrix Science http://www.matrixscience.com/distiller.html
HD-Examiner Sierra Analytics http://massspec.com/hdexaminer/
SigmaPlot Systat Software Inc www.sigmaplot.co.uk/products/sigmaplot/
CD Tools (Lees et al., 2004) N/A
Other
Vanguard C18 pre-column Waters Cat# 186003975CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tom D.
Bunney (t.bunney@ucl.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
For protein purification, E. coliC41 (DE3) transformedwith either the KanR plasmid pOPINS or pJ821 and the SpecR pCDF-Duet were
plated on TB/Kan/Spec agar plates. Colonies were grown at 37 C in 500 ml TB medium or M9 minimal medium supplemented with
0.1 g/l kanamycin and 0.05 g/l spectinomycin until an OD600nm of between 0.8 and 1.2 was reached. Cultures were then cooled
to 15C. Protein expression was induced by the addition of 0.1 mM IPTG (for pOPINS) or 1 mM rhamnose and 0.1 mM IPTG
(for pJ821) to the cultures and incubation at 15 C for 16 h.
METHOD DETAILS
Cloning, Protein Expression & Site-Directed Mutagenesis
Preparation of Kinase Domains, Cdc37, Hsp90a and Casein Kinase II
The FGFR3 kinase domain (amino acids 455-768 of human FGFR3) was cloned into either pOPINS (OPPF, Oxford, UK) or pJ821
(DNA2.0, Menlo Park, USA) using In-Fusion cloning (Clontech, Mountain View, USA). Further procedures were similar as described
in (Patani et al., 2016). Plasmids were transformed into C41 (DE3) cells harbouring a co-expression plasmid, pCDF-Duet, expressing
lambda phosphatase under an IPTG inducible promoter. Transformed colonies were selected on agar plates containing Terrific
Broth (TB), 10 mM Glucose, 100 mg/mL kanamycin and 50 mg/mL spectinomycin overnight at 37 C. Colonies were inoculated
into liquid media containing the same components as the solid media and grown in baffled flasks to an optical density (OD600) of
0.8 to 1.2. Cultures were cooled to 15 C for 1 hour and then induced through the addition of 0.1 mM IPTG (for pOPINS) or 1 mM
rhamnose and 0.1 mM IPTG (for pJ821) for 16 hours. Cells were pelleted and stored at -20 C until required. Mutations within all con-
structs were introduced using the site directed mutagenesis method (Agilent Technologies) and verified by sequencing of the com-
plete open reading frame.e2 Structure 26, 446–458.e1–e8, March 6, 2018
The sB-RafV600E (448-723 of human B-Raf) was purchased as a synthetic gene and cloned into pJ821 (resulting in a N-terminal
His-SUMO tag). The protein incorporated mutations described in (Tsai et al., 2008). The expression was carried out identically as
for FGFR3.
Cdc37, Hsp90a and Casein Kinase II
Expression plasmids for human Cdc37 (in pET28), Hsp90a (in pRSET) and Casein Kinase II (in pTWO), were kindly provided by C.
Vaughan (Vaughan et al., 2006). Plasmids were transformed into C41 (DE3) cells and selected overnight on LB plates containing
the appropriate antibiotic. Several colonies were inoculated into 0.5 L of 2xYT media containing appropriate antibiotics and grown
to an OD600 of 0.4. Cultures were cooled to 25
C for 2 hours and then expression was induced through the addition of 1 mM IPTG.
Cultures weremaintained overnight at 25 C and harvested the following day by centrifugation and subsequent storage at -20 C. For
the production of Cdc37 with phosphorylated serine 13, the Cdc37 was co-expressed with the vector for CKII.
Expression of FGFR3 Kinase Domain Constructs in Minimal Medium (for 15N or 15N /13C Labelling)
Constructs were transformed as outlined above. Colonies were inoculated into 2 mL of TB containing 10 mM Glucose, 100 mg/mL
kanamycin and 50 mg/mL spectinomycin and grown for 4 hours at 37 C in an orbital shaker at 200 rpm. Minimal media agar plates
were prepared containing 100 mg/mL kanamycin and 50 mg/mL spectinomycin with 3 plates necessary for every 500 mL planned
culture. Each plate was spread with 100 mL of the TB culture and bacterial lawns allowed to grow overnight at 37 C. Bacteria
were scraped from the plates into 500 mL of minimal media containing a source of either 15N-ammonium sulphate (1g/L) alone or
a combination of 15N-ammonium sulphate (1g/L) and 13C- glucose (5g/L). Cultures were grown in baffled 2 litre flasks for 1 hour
at 37 C and then 2 hours at 15 C. The cultures were induced with the addition of 0.1 mM IPTG (for pOPINS) or 1 mM rhamnose
and 0.1 mM IPTG (for pJ821) for 16 hours. Bacteria were pelleted and stored at -20 C until processed.
Expression of FGFR3 Kinase Domain Constructs in Minimal Medium for Selective Unlabelling (for 15N Labelling with
Particular Amino Acid Residues Unlabelled)
Constructs were transformed as outlined above. Colonies were inoculated into 2 mL of TB containing 10 mM Glucose, 100 mg/mL
kanamycin and 50 mg/mL spectinomycin and grown for 4 hours at 37 C in an orbital shaker at 200 rpm. Minimal media agar plates
were prepared containing 100 mg/mL kanamycin and 50 mg/mL spectinomycin with 3 plates necessary for every 500 mL planned
culture. Each plate was spread with 100 mL of the TB culture and bacterial lawns allowed to grow overnight at 37 C. Bacteria
were scraped from the plates into 500 mL of minimal media containing a source of 15N-ammonium sulphate (1g/L) and 1g/L of a
particular amino acid or combination of amino acids. Cultures were grown in baffled 2 litre flasks for 1 hour at 37 C and then 2 hours
at 15 C. The cultureswere inducedwith the addition of 0.1mM IPTG (for pOPINS) or 1mM rhamnose and 0.1mM IPTG (for pJ821) for
16 hours. Bacteria were pelleted and stored at -20 C until processed.
Expression of FGFR3 Kinase Domain Constructs inMinimal Medium for Selective Labelling (for 15N Labelling with Only
Particular Amino Acid Residues)
Constructs were transformed as outlined above. Colonies were inoculated into 2 mL of TB containing 10 mM Glucose, 100 mg/mL
kanamycin and 50 mg/mL spectinomycin and grown for 4 hours at 37 C in an orbital shaker at 200 rpm. Minimal media agar plates
were prepared containing 100 mg/mL kanamycin and 50 mg/mL spectinomycin with 3 plates necessary for every 500 mL planned
culture. Each plate was spread with 100 mL of the TB culture and bacterial lawns allowed to grow overnight at 37 C. Bacteria
were scraped from the plates into 500 mL of minimal media containing unlabelled ammonium sulphate and glucose and 1g/L of
all amino acid (except tyrosine which was added at 0.5 g/L) and the amino acid to be labelled was not added at this point. Cultures
were grown in baffled 2 litre flasks for 1 hour at 37 C and then 2 hours at 15 C. The labelled amino acid was added and then the
cultures were induced with the addition of 0.1 mM IPTG (for pOPINS) or 1 mM rhamnose and 0.1 mM IPTG (for pJ821) for 16 hours.
Bacteria were pelleted and stored at -20 C until processed.
Expression of FGFR3 Kinase Domain Constructs in Deuterated Minimal Medium (for 2H/15N or 2H/15N /13C Labelling)
Constructs were transformed as outlined above. Colonies were inoculated into 2 mL of TB containing 10 mM Glucose, 100 mg/mL
kanamycin and 50 mg/mL spectinomycin and grown for 4 hours at 37 C in an orbital shaker at 200 rpm. Minimal media agar plates
were preparedwith deuterium oxide instead of water and contained 100 mg/mL kanamycin and 50 mg/mL spectinomycin with 3 plates
necessary for every 500mL planned culture. Each plate was spread with 100 mL of the TB culture and bacterial lawns allowed to grow
for 48 hours at 37 C. Bacteria were scraped from the plates into 500 mL of minimal media prepared with deuterium oxide and con-
taining a source of either 15N-ammonium sulphate (1g/L) alone or a combination of 15N-ammonium sulphate (1g/L) and 13C- glucose
(5g/L). Cultures were grown in baffled 2 litre flasks for 2 hours at 37 C and then 4 hours at 15 C. The cultures were induced with the
addition of 0.1 mM IPTG (for pOPINS) or 1 mM rhamnose and 0.1 mM IPTG (for pJ821) for around 66 hours. Bacteria were pelleted
and stored at -20 C.
Protein Purification
Generally, pellets were retrieved from the -20 C and resuspended in 20 mL of chilled Lysis Buffer (25 mM Tris.Cl, 250 mM NaCl,
40 mM Imidazole, 10 mM Benzamidine, 1 mM MgCl2 and 100 mM CaCl2, 100 mg/mL lysozyme, pH 8.0). Resuspension was accom-
plished by placing the pellets on an orbital shaker set at 200 rpm at 4 C for 30minutes. Lysis was continued by the addition of 5mL of
a solution of 10% (v/v) Triton-X-100 and 1 Kunit of bovine pancreatic DNAse I, on the orbital shaker at 200 rpm. at 4 C for 1 hour.
Clarification of the lysate was performed by centrifugation of the sample for 1 hour at 4 Cat 13,000 rpm in a JA-25.50 rotor (Beckman
Coulter). All chromatography steps were performed on an Akta Explorer 10 (GE Healthcare, Amersham, UK) system.Structure 26, 446–458.e1–e8, March 6, 2018 e3
Protein Purification Steps for Kinase Domains of FGFR1-4 and FGFR3 Variants
The clarified lysates were loaded onto a 5mLHisTrap column (GE Healthcare, Amersham, UK). Proteins were washed with His Buffer
A (25 mM Tris.Cl, 500 mMNaCl, 40 mM Imidazole, 1 mM TCEP, pH 8.0) and eluted with a 20-column volume gradient to His Buffer B
(25mMTris.Cl, 500mMNaCl, 500mM Imidazole, 1 mMTCEP, pH 8.0). Eluted fractions containing protein were pooled and 100 mL of
10mg/mL Ulp1 protease was added per 20mL of eluted recombinant protein. Removal of the purification tag progressed overnight in
Dialysis Buffer (25 mMTris.Cl, 1 mM TCEP, pH 8.0). Cleaved proteins were passed again over a HisTrap column using Dialysis Buffer
as loading and wash buffer. Proteins that did not bind to the column were collected and subsequently injected on a 5 mL HiTrap Q
(GE Healthcare, Amersham, UK) equilibrated in Q Buffer A (25 mM Tris.Cl, 20 mM NaCl, 1 mM TCEP, pH 8.0). Proteins were eluted
over 20 column volumes to 50% of Q Buffer B (25 mM Tris.Cl, 1 M NaCl, 1 mM TCEP, pH 8.0) and eluted proteins collected in 10 mL
fractions. Those fractions containing FGFR kinase domains were pooled and injected onto a Superdex 200 26/60 column (GEHealth-
care, Amersham, UK) equilibrated in either NMR buffer (50mMPIPES.NaOH, 50mMNaCl, 2mMTCEP, 1mMEDTA, pH 7.0) or Stan-
dard Gel Filtration Buffer (25 mM Tris.Cl, 150 mMNaCl, 1 mM TCEP, pH 8.0). Monomeric FGFR3 kinase domain was concentrated in
Vivaspin 10 kDam.w.c.o. (Vivaproducts, Littleton, USA) concentrating units and quantified using a Nanodrop (Thermo Scientific, UK)
using calculated molecular weight and extinction coefficients. Proteins were stored between 5 and 20 mg/mL, after snap freezing in
liquid N2, at -80
C.
Purification of HSP90a, CDC37Apo (Non-Phosphorylated Cdc37) and CDC37pSer13 (Phosphorylated Cdc37)
The clarified lysates were loaded onto a 5mLHisTrap column (GE Healthcare, Amersham, UK). Proteins were washed with His Buffer
A (25 mM Tris.Cl, 500 mMNaCl, 40 mM Imidazole, 1 mM TCEP, pH 8.0) and eluted with a 20-column volume gradient to His Buffer B
(25mM Tris.Cl, 500mMNaCl, 500mM Imidazole, 1 mM TCEP, pH 8.0). Eluted fractions containing protein were dialysed overnight in
Low Salt Buffer (25 mM Tris.Cl, 1 mM TCEP, pH 8.0). Proteins were subsequently injected onto a 5 mL HiTrap Q (GE Healthcare,
Amersham, UK) equilibrated in Q Buffer A (25 mM Tris.Cl, 20 mM NaCl, 1 mM TCEP, pH 8.0). Proteins were eluted over 20 column
volumes to 50% of Q Buffer B (25 mM Tris.Cl, 1 M NaCl, 1 mM TCEP, pH 8.0) and eluted proteins collected in 10 mL fractions. Those
fractions containing the required protein were pooled and injected onto a Superdex 200 26/60 column (GE Healthcare,
Amersham, UK) equilibrated in standard Gel Filtration Buffer (25 mM Tris.Cl, 150 mM NaCl, 1 mM TCEP, pH 8.0). Purification was
monitored using SDS-PAGE and the relevant purified proteins were concentrated in Vivaspin 10 kDa m.w.c.o. (Vivaproducts, Little-
ton, USA) concentrating units and quantified using a Nanodrop (Thermo Scientific, UK) using calculatedmolecular weight and extinc-
tion coefficients. Proteins were stored between 5 and 20 mg/mL, after snap freezing in liquid N2, at -80
C. Phosphorylation at serine
13 on CDC37 was verified using an antibody that specifically recognises this modification. This form was used in most experiments
and designated as Cdc37 except when used to compare non- phosphorylated and phosphorylated forms.
sB-RafV600E Protein Purification
The clarified lysates were loaded onto a 5mLHisTrap column (GE Healthcare, Amersham, UK). Proteins were washed with His Buffer
A (25 mM Tris.Cl, 500 mMNaCl, 40 mM Imidazole, 1 mM TCEP, pH 8.0) and eluted with a 20-column volume gradient to His Buffer B
(25mMTris.Cl, 500mMNaCl, 500mM Imidazole, 1 mMTCEP, pH 8.0). Eluted fractions containing protein were pooled and 100 mL of
10mg/mL Ulp1 protease was added per 20 mL of eluted recombinant protein. The protein was not dialysed. After 16 hours of cleav-
age the protein was desalted using four 5mL HiTrap Desalting columns (GE Healthcare) connected in series into Low Salt Buffer
(25 mM Tris.Cl, 20 mM NaCl, 5%(v/v) glycerol and 1 mM TCEP, pH 7.0). The desalted mixture was then injected on a 5 mL HiTrap
Q (GE Healthcare, Amersham, UK) equilibrated in B-Raf Q Buffer A (25 mM Tris.Cl, 20 mM NaCl, 5%(v/v) glycerol, 1 mM
TCEP, pH 7.0). Proteins were eluted over 20 column volumes to 50% of B-Raf Q Buffer B (25 mM Tris.Cl, 1 M NaCl, 5%(v/v) glycerol,
1 mM TCEP, pH 7.0) and eluted proteins collected in 10 mL fractions. Those fractions containing B-Raf kinase domains were pooled
and injected onto a Superdex 200 26/60 column (GE Healthcare, Amersham, UK) equilibrated in B-Raf Gel Filtration Buffer
(25 mM Tris.Cl, 500 mMNaCl, 1 mM TCEP and 1mMMgCl2, pH 7.0). Monomeric B-Raf kinase domain was concentrated in Vivaspin
10 kDa m.w.c.o. (Vivaproducts, Littleton, USA) concentrating units and quantified using a Nanodrop (Thermo Scientific, UK) using
calculated molecular weight and extinction coefficients. Proteins were stored between 3 and 5 mg/mL, after snap freezing in liquid
N2, at -80
C.
Analysis of Protein Complexes
For analytical SEC, binary complexes were prepared with a kinase concentration of 15 mMand the Cdc37 concentration of 15 mM in a
total volume of 40 mL. Ternary complexes were prepared similarly but included 30 mMof Hsp90a in addition to the kinase and Cdc37.
Complexes were incubated at 4 C for 15 min before loading onto an analytical Superdex 200 Increase column (24 mL, GE Health-
care) equilibrated in Gel Filtration Buffer (25 mM Tris.Cl, 150 mM NaCl, 1 mM TCEP, pH 8.0) at 4C. Aliquots from 750 mL fractions
were analyzed by SDS-PAGE and Coomassie staining; for samples containing FGFR3 kinase domain, aliquots were also used in
ELISA (see below). For analysis of the effect of FGFR inhibitors on binary and ternary complex formation, the following compounds
were used at 30 mM: Dovitinib, AZD4547 and PD173074 (all from Stratech Scientific Ltd.). In all cases the DMSO concentration was
less than 0.15 %(v/v).
For analysis of binary complexes in PD experiments, 50 mg portions of Bait protein (Cdc37 or Hsp90 with HIS-tags) were immo-
bilised on 100 mL of Talon resin (Clontech) in Wash Buffer (25 mM Tris.Cl, 150 mM NaCl, 1 mM TCEP, 0.1 %(v/v) Triton-X-
100, pH 8.0) by incubation for 15 min at 4 C on a rotating wheel. The Talon beads were subsequently washed three times with
500 mL of cold Wash Buffer to remove unbound protein. The target protein (FGFR3 kinase domain variants or sB-RafV600E) (amounts
specified in individual figures) was added to the immobilised Bait in 500 mL of Wash Buffer and incubated at 4 C for 1 hour on ae4 Structure 26, 446–458.e1–e8, March 6, 2018
rotating wheel. The Talon beads werewashed five times through the addition of 500 mL of coldWash Buffer and gentle agitation of the
beads followed by thorough aspiration. Proteins were eluted from the Talon beads through the addition of 50 mL Sample Buffer and
10 mL of 500 mM Imidazole. Proteins were subsequently denatured through a 5 min incubation at 95 C and then loaded onto a 12%
SDS-PAGE for separation and visualization by Coomassie staining or, when specified, byWestern Blotting [FGFR3 specific antibody
(LS-C214248, LifeSpan BioSciences)].
To quantify amounts of kinases present in binary and ternary complexes the gels were imaged using a SyngeneGel Documentation
System and bands were quantified using Image Studio Lite (Licor). For comparison of FGFR3 variants, ELISA was also used to
analyze individual samples and SEC fractions. ELISA plates (Immuno F96 Maxisorp, Nunc) were coated with a monoclonal (IgG)
anti-FGFR3 antibody (55463, MP Biomedical) that had been diluted 1:8000 in Phosphate Buffered Saline (PBS) and incubated for
16 hours at 4 C. The plate was washed once with ELISA Buffer (PBS containing 0.2%(v/v) Tween-20) and subsequently blocked
using Sample/Antibody Diluent Buffer (PBS, 2%(w/v) BSA, 0.2%(v/v) Tween-20) and incubated for one hour at 25 C in an orbital
shaker. The plate was washed twice with ELISA Buffer. Several serial dilutions were prepared and 100 mL aliquots applied to the
ELISA plate and incubated at room temperature for one hour. The ELISA plate was washed five times in ELISA buffer. One
hundred mL of a 1:25,000 diluted (in ELISA Buffer) HRP-conjugated rabbit polyclonal anti FGFR3 antibody (LS-C214248, LifeSpan
Bioscience) was added to each well and incubated for one hour at 25 C in an orbital shaker. The ELISA plate was washed five times
in ELISA buffer. The colourimetric substrate (555214, BD Bioscience) was added following manufacturer’s instructions and the plate
read at 460 and 520 nm in a FLUOstar plate reader (BMG Labtech). Concentrations were interpolated from the standard curves using
GraphPad Prism.
The data obtained by analyses of binary and ternary complexes were presented either as one representative image for two
(or more) experiments, together with the quantitation of KDs corresponding to the image shown or, when stated in the figure legends,
amounts of KDs were expressed as means +/- the standard deviation (SD) of three experiments.
Kinase Auto-Phosphorylation
All purified FGFR3 kinase domain proteins had been prepared in the presence of lambda phosphatase and were therefore in an
unphosphorylated state. Aliquots of FGFR3 proteins (0.5 mg) were incubated in Kinase Buffer (25 mM Tris.Cl, 150 mM NaCl,
10 mM MgCl2, 1 mM MnCl2, 2 mM NaVO4, 0.1 mM TCEP, pH 8.0) and either CDC37
Apo (0-5 molar ratio) or Urea (0-5 M) for
30 min at room temperature. Subsequently, phosphorylation was initiated through the addition of 1 mMATP and allowed to continue
for 30 min at room temperature. Reactions were terminated through the addition of Sample Buffer and the proteins were denatured
and separated on a 10 % SDS-PAGE. Proteins were identified through immunoblotting using antibodies recognising FGFR1 phos-
phorylated tyrosines 654 (ab70959, AbCam) and 766 (ab59180, AbCam) that presumably recognise FGFR3 phospho-tyrosines 648
and 760 respectively. Bands were detected with ECL Prime (GE Healthcare, Amersham, UK) and imaged digitally using a FujiFilm
detector (FujiFilm Luminescent Image Analyzer, LAS-1000 CH). Bands were quantified using Image Studio Lite (LiCor). The data
are shown as representative Western Blots and values obtained by image quantitation from three experiments plotted as means +/-
the SD.
Thermofluor Assay
A PCR microplate was filled with 20 mL protein solution (1 mg mL-1 or 30 mM) of kinase variants in Thermofluor buffer (25 mM Tris.Cl,
150 mMNaCl, 1 mM TCEP, pH 8.0). Five mL of SYPROOrange dye (ThermoFisher) was added to give a final dye dilution of 500 times
the stock and a final sample volume of 25 mL. The microplates were sealed with an adhesive optical clear seal. Samples were heated
using a RT-PCR instrument (iQ5, BioRad) and the increase in fluorescence monitored from 10 C to 90 C in 1 C increments. The
temperature at which 50 % of the protein is unfolded and bound to the fluorescent dye (apparent melting temperature, Tm) corre-
sponds to the inflexion point of the slope. Raw data were plotted and analyzed using GraphPad Prism (http://www.graphpad.
com). The transition midpoint was calculated automatically using an in-house written script. In experiments where inhibitors or nu-
cleotides were added to the protein, a concentration of 60 mMwas used. The final DMSO concentration in these experiments never
exceeded 0.3% (v/v). For each protein sample three to four aliquots were analyzed in the same experiment and data presented as the
means +/- the SD.
ITC
Heats of interaction were measured on a VP-ITC system (Microcal) with a cell volume of 1.458 mL.
For titrations of FGFR and Cdc37, the FGFR3 kinase domain protein was dialyzed for 16 hours in ITC buffer (25 mM Tris.Cl,
50 mM NaCl, 5 mM MgCl2 and 0.1 mM TCEP, pH 7.5) at 4
C. FGFR3 WT or FGFR3I538F variant were loaded in the sample cell
(FGFR3WT at 19.4 mMand FGFR3I538F at 16.9 mM) and titrated with Cdc37Apo in the syringe (211.7 mM). The titrations were performed
while samples were being stirred at 260 revolutions per minute at 20 C. A total of 20 injections were carried out, with 15 mL injected
each time (except the first injection, when 3 mL was injected), and a 5 min interval between each injection to allow the baseline to
stabilize. The data were fitted with a single site model to calculate the number of binding sites (n), the binding constant (Ka), the
change in enthalpy (DH), and change in entropy (DS) using Origin software (Microcal, 2004).Structure 26, 446–458.e1–e8, March 6, 2018 e5
CD
CD spectra were collected on a Jasco J-715 spectropolarimeter equipped with a temperature controller. The protein samples were
prepared in 25 mM sodium phosphate, pH 7.5 with extensive dialysis. The CD Spectra were recorded at 20 C with a step size of
1.0 nm, a bandwidth of 1 nm and an averaging time of 2.0 sec. Measurements were performed in a 1 mm path length quartz
SUPRASIL cell (Hemlla, Germany) using 2.5 mM of proteins. Three scans were applied continuously and the data were averaged.
The CD spectra were averaged, smoothed and processed after blank subtraction and converted to the presented units using CDtool
software (Lees et al., 2004).
HDX-MS
Samples were prepared by incubating the proteins of interest at 5 mM either alone or in the presence of 7.5 mMbinding partner on ice
for 30 minutes in a buffer consisting of 25 mM Tris.Cl pH 8.0, 150 mM NaCl and 1 mM TCEP. Ten mL of each of these reactions was
mixed rapidly with 40 mL of Deuterium Buffer (20 mM, Tris.Cl pH 8.0, 150 mM NaCl, 1 mM TCEP, 94.8%(v/v) D2O (Acros Organics),
producing a final D2O concentration of 75.4 %(v/v). Four incubation conditions were performed in triplicate: three seconds on ice
(which slows the exchange reaction by approximately tenfold, and is such representing a 0.3 second timepoint), three seconds at
22 C, 30 seconds at 22 C and 300 seconds at 22 C. The reactions were quenched by the addition of 20 mL cold Quench buffer,
consisting of 5 M Guanidinium Chloride and 8.4%(v/v) Formic Acid, followed by snap freezing in liquid nitrogen. Samples were then
stored at -80C.
The samples were sequentially thawed and injected onto anUltra Performance Liquid Chromatography (UPLC) system submerged
in ice. The sample was run over two in-series Poroszyme immobilised pepsin cartridges (Applied Bioscience) at a rate of 0.15mL/min
for threeminutes, and the digested peptides were collected on a 1.7 mmAcquity UPLCBEHC18 VanGuard pre-column (Waters). The
trap was then switched in-line to an Acquity UPLC BEH C18 column (Waters), and a 20 minute 5 to 45%(v/v) gradient of acetonitrile
was passed over the column to elute the peptides, followed by a 4-minute wash of 76 %(v/v) acetonitrile. The mass of the eluted
peptides was subsequently determined using a Waters Xevo quadrupole time of flight mass spectrometer. The instrument was
acquiring for 30 minutes over mass/charge ratios of 350 to 1500, using an electrospray ionisation source operated at a capillary tem-
perature of 225 C and a spray voltage of 3.5 kV.
Peptides were identified from non-deuterated samples analysed using tandem mass spectrometry. A tolerance of 15 parts per
million was used in the MS observations, and a tolerance of 0.2 Daltons in the MS/MS observations. The resulting datasets were an-
alysed using Mascot Distiller (Matrix Science). Any peptide with a Mascot score%10 was excluded from further analysis. Centroid
values were determined initially automatically using HD-Examiner software (Sierra Analytics), followed by manual quality control of
each peptide. Because of the overlap from the shift in isotopic envelope observed upon deuterium incorporation, and peptides pre-
sent from binding partners, additional peptides were removed from the dataset. All mentions of deuterium levels in the text and fig-
ures are relative values, as no fully deuterated sample could be obtained due to the buffer composition.
The data are expressed as means +/- the SD for triplicates at a given time point.
NMR
Uniformly 15N,13C,2H-labelled, uniformly 15N-labelled, selectively-labelled and selectively-unlabelled samples of FGFR3WT, free or in
complex with non-labelled Cdc37, were prepared in 50 mM PIPES-NaOH, 50 mM NaCl, 5 mM TCEP and 1 mM EDTA (pH 7.0) con-
taining 5% D2O. The GFR3
I538F variant, free and in complex with Cdc37, was prepared in an identical manner to that of GFR3WT,
except that FGFR3I538F singly labelled with 15N only was used for all experiments. All samples were approximately 200-300 mL
and between 77 and 230 mM concentration in 5 mm Shigemi tubes. NMR spectra were recorded at temperatures ranging from
303K to 283K on Bruker Avance III or Avance III HD 600, 750, 800 or 950 MHz spectrometers equipped with 5mm QCI-P or TCI
z-axis gradient Cryoprobes. Standard TROSY-detected triple-resonance experiments (Salzmann et al., 1998) and TROSY-detected
HSQC experiments with water flip-back and WATERGATE pulses (Pervushin et al., 1998) were recorded as detailed previously.
All data were processed using NMRPipe and NMRDraw (Delaglio et al., 1995) and analysed with CCPNMR Analysis (Vranken
et al., 2005).
Assignments
1H-15N TROSY-HSQC spectra of uniformly 15N,13C,2H-labelled FGFR3WT, in free (230 mM) and PD173074-bound (1.30 equivalents of
PD173074) forms were recorded at 303K as detailed previously (Bunney et al., 2015). The addition of PD173074 improved stability
and spectral quality and was, therefore, used to facilitate assignment of free FGFR3WT. A 78% assignment of the non-Pro backbone
amide resonances of the PD173074-bound FGFR3 HSQC spectrum was achieved using TROSY-based triple-resonance experi-
ments (HNCO, HNCA, HN(CA)CB, HN(CO)CA, HN(CA)CO HNCB). Assignment of apo FGFR3WT backbone amide and carbon reso-
nances was accomplished by the use of TROSY triple-resonance experiments for backbone assignment (HNCA, HNCACB and
HNCO). Samples of apo FGFR3 with selectively-labelled phenylalanine and leucine (U-15N-Phe, U-15N,13C-Leu) were used to solve
ambiguities together with the assignment of PD173074-bound FGFR3 and by comparison to backbone assignments of free FGFR1
(Vajpai et al., 2014) and FGFR2 kinases (D. Cowburn and K. Dutta, personal communication). Ultimately, assignment of 75% of non-
Pro backbone amides was achieved. Backbone assignments for PD173074-bound FGFR3WT and apo FGFR3WT have been depos-
ited in the BioMagResBank database (accession numbers 27083 and 27082, respectively).e6 Structure 26, 446–458.e1–e8, March 6, 2018
Titration with Cdc37
Uniformly 15N-labelled FGFR3WTwas titrated with non-labelled Cdc37 at various molar ratios (1:0.75, 1:1.9 and 1:3 FGFR3WT:Cdc37)
and 1H-15N TROSY-HSQC spectra recorded for each titration point. Spectra of the FGFR3WT:Cdc37 complexes were recorded at
298 K and 283 K, the latter to improve sample stability. A series of FGFR3WT:Cdc37 complex spectra were also recorded at temper-
atures between these two extremes, and these used to track perturbation of backbone amide assignments due to temperature. The
titration of FGFR3I538F variant with Cdc37 was in a similar manner to FGFR3WT; 1H-15N TROSY-HSQC spectra were recorded for this
variant in free and Cdc37 complex forms (1:0.25 and 1:0.50molar ratios) at 283K. Transfer of backbone amide assignments from free
FGFR3WT to free FGFR3I538F was completed where unambiguous, and CSPs calculated for those mutually assigned resonances,
quantified as a combined chemical shift (Dd) wherein Dd = [(0.2*d15NWT/I538F)
2+(d1HWT/I538F)
2]0.5. Comparison of 1H-15N TROSY-
HSQC spectra of FGFR3WT:Cdc37 (1:0.70) and FGFR3I538F:Cdc37 (1:0.70) revealed the presence of sharp, random coil cross-peaks
in the I538F complex spectrum at similar chemical shifts to those in the WT equivalent.
The identity of the new, slowly-exchanging amide cross-peaks was achieved using several approaches. Firstly, standard triple-
resonance 3D TROSY-HNCA and TROSY-HN(CA)CB spectra were recorded on a 15N,13C,2H-labelled FGFR3WT:unlabelled
Cdc37 complex sample to obtain connectivity and Ca/Cb shift information to assist residue spin systems. Secondly, the HN
and 15N random coil chemical shifts of FGFR3 backbone amides were predicted using a method described previously (Han et al.,
2011) and compared to the experimentally-observed cross-peaks. Assignment was also facilitated using a selectively-unlabelled
FGFR3:Cdc37 (1:1) complex composed of U-15N-FGFR3 with unlabelled Lys and Leu residues (-KL). All complexes were prepared
using non-labelled Cdc37. Comparison of amide cross-peaks in the 1H-15N TROSY-HSQC spectra of the –KL selectively-unlabelled
FGFR3:Cdc37 complex to those in a U-15N-labelled FGFR3:Cdc37 reference spectrum (1:0.75) was used to identify successfully un-
labelled residues. All selectively unlabelled and reference spectra were recorded at 298K. To account for signal intensity variability
due to sample concentration and stability, selectively unlabelled spectra were normalised with respect to the reference spectrum
using G481, G533, G549 and G574 as reference peaks. Following normalisation, the peak height of each assigned cross-peak in
the selectively unlabelled spectrumwas divided by the intensity of the corresponding cross-peak in the reference spectrum to obtain
an intensity ratio wherein 1 = equivalent intensities and 0 = completely unlabelled. To account for stochastic variation of peak height at
different signal to noise ratios, peak height ratios for intensities at signal to noise ratios of 30, 20, 10 and 8 were simulated, and a
confidence threshold corresponding to the mean peak height ratio minus 3 standard deviations was calculated for each. Backbone
amide cross-peaks in the FGFR3:Cdc37 spectra were categorised with respect to their peak height signal:noise, then their peak
height ratios compared to the appropriate confidence threshold. Only those cross-peaks with peak height ratios below their respec-
tive threshold are considered in the analysis.
SAXS
Synchrotron radiation small-angle X-ray scattering data were acquired for Cdc37, FGFR3I538F variant and their complex at the P12
beamline of the European Molecular Biology Laboratory (EMBL) at the storage ring PETRA-III at the Deutsches Elektronen-Synchro-
tron (DESY), Hamburg. Using a Pilatus 2M detector at a sample-to-detector distance of 3.1 m and a wavelength of 0.124 nm, a mo-
mentum transfer range of 0.025< s < 5.0 nm-1 was covered (s = 4psinq/l, where 2q is the scattering angle). For each sample, SAXS
data were acquired for a dilution series measured with the robotic sample changer (batch mode) and for an in-line size exclusion
chromatography run (SEC-SAXS). Radial averaging and, for the batch mode data, frame averaging and buffer subtraction, were
done using the SASFLOW within ATSAS 2.8 (Franke et al., 2017) analysis pipeline.
For Cdc37, the data from the batchmode dilution series (three concentrations ranging from 4.2mg/mL to 1.1 mg/mL) were extrap-
olated to zero concentration using ALMERGE within ATSAS 2.8 (Franke et al., 2017). For FGFR3I538F the scattering pattern was
extracted from the SEC-SAXS intensity data (weighted for the estimated errors) using the non-negative matrix factorization within
ATSAS 2.8 (Franke et al., 2017) (NMF) algorithm as implemented in the scikit-learn package within ATSAS 2.8 (Franke et al.,
2017). The NMF fit was done with four components (one of which corresponds to the buffer), and the component with Guinier radius
closest to that expected for FGFR3I538F was selected for further analysis. This curve was then cropped using DATCROP within
ATSAS 2.8 (Franke et al., 2017) to remove the data at the smallest angles affected by incorrect buffer suppression. For the
FGFR3I538F:Cdc37 complex, the data from the batch mode dilution series (three concentrations ranging from 3.8 mg/mL to
1.0 mg/mL) were extrapolated to zero concentration using ALMERGE (Franke et al., 2017) then cropped using DATCROP (Franke
et al., 2017) to remove the data at the smallest angles affected by interparticle interactions.
The forward scattering (I(0)) and the radii of gyration (Rg) were evaluated using the Guinier approximation assuming that at very
small angles, s < 1.3/Rg, the intensity can be represented as IðsÞ= Ið0Þexp
 
ðsRgÞ2
3
!
: These parameters were also computed from
the entire scattering pattern using the indirect transform package GNOMwithin ATSAS 2.8 (Franke et al., 2017), which also provided
the distance distribution function P(r) and the maximum dimensions of the particles (Dmax). The molecular mass (MM) of the solute
was evaluated by comparison of the forward scattering with that from a reference solution of bovine serum albumin (MM = 66 kDa).
Since the FGFR3I538F data are extracted from a SEC-SAXS experiment, the forward scattering is not directly comparable with the
reference solution and therefore no estimate of molecular mass is made. The particle volumes were computed using the Porod
invariant (Svergun et al., 2013). Ambiguity analysis was performed with AMBIMETER within ATSAS 2.8 (Franke et al., 2017).Structure 26, 446–458.e1–e8, March 6, 2018 e7
Two-phase ab initiomodels were reconstructed by MONSA using a dummy atom radius of 0.3 nm and a spherical search volume
with diameter Dmax = 16 nm (equal to the experimental maximum size of the complex) and P1 symmetry. The relative volumes of the
individual phases were set proportionally to the number of amino acid residues in the respective proteins. The three SAXS curves for
Cdc37, FGFR3I538F and their complex were fitted simultaneously – the curves from individual proteins against the individual phases of
the model, and the curve from the complex against the whole model. The MONSA calculations were repeated twenty times using
different random seeds and the resulting models grouped into clusters using DAMCLUST within ATSAS 2.8 (Franke et al., 2017).
Rigid body modelling was carried out using CORAL within ATSAS 2.8 (Franke et al., 2017), using the available crystal structures of
FGFR3 (PDB ID 4K33) and the C-terminal part of Cdc37 (PDB ID 1US7) together with the NMR structure of the N-terminal part of
Cdc37 (PDB ID 2NCA, model A). Each of these three domains was free to move independently in the fit (constrained by the linker
between 1US7 and 2NCA), but since the 4K33 and 1US7 structures have missing loops these were each modelled as two separate
domains (before and after the loop) with fixed relative positions. The three SAXS curves were fitted simultaneously, with additional
restraints using the interface information from the hydrogen-deuterium exchange mass spectrometry data. Specifically, the pro-
tected residues from FGFR3 kinase (Y607-L624, F667-F680, R728-L748) were requested to contact Cdc37. Reciprocally, the resi-
dues Y4-L28, R270-D293, F309-M316, L317-L341 from Cdc37 were requested to contact either FGFR3 or the other domain of
Cdc37. The CORAL calculations were repeated twenty times using different random seeds and the resulting models grouped into
clusters using DAMCLUST (Franke et al., 2017).
The experimental SAXS curves have been submitted to the Small Angle Scattering Biological Data Bank (SASBDB) with the acces-
sion codes; SASDBP9 for human Hsp90 co-chaperone Cdc37 protein (Cdc37), SASDBQ9 for human Hsp90 co-chaperone Cdc37 in
complex with fibroblast growth factor receptor 3 kinase domain and SASDBR9 for human fibroblast growth factor receptor 3 kinase
domain.
DATA AND SOFTWARE AVAILABILITY
Backbone assignments for PD173074-bound FGFR3WT and apo FGFR3WT have been deposited in the BioMagResBank database
(accession numbers 27083 and 27082, respectively). The experimental SAXS curves have been submitted to the Small Angle
Scattering Biological Data Bank (SASBDB) with the accession codes; SASDBP9 for human Hsp90 co-chaperone Cdc37 protein
(Cdc37), SASDBQ9 for human Hsp90 co-chaperone Cdc37 in complex with fibroblast growth factor receptor 3 kinase domain
and SASDBR9 for human fibroblast growth factor receptor 3 kinase domain.e8 Structure 26, 446–458.e1–e8, March 6, 2018
